Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Carcinoma
Shots:
- The NMPA has approved the IND application of ipilimumab biosimilar HLX13 (recombinant anti-CTLA-4 fully human mAb) for the treatment of HCC. HLX13 was developed by Henlius in accordance with Chinese Biosimilar Guidelines
- The head-to-head pre-clinical studies results showed a high similarity or no significant difference b/w HLX13 and originator ipilimumab. The company continues to broaden its innovative layout in immuno-oncology combination therapy to bring affordable and high-quality innovative biologics to patients globally
- HLX13 is designed to block T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of reactive T-effector cells
Ref: Henlius | Image: Henlius
Related News:- Henlius Receives NMPA's IND Approval for its HLX13 (biosimilar- ipilimumab)
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
